Pliant Therapeutics, Inc. (PLRX)

Over the past six months, Pliant Therapeutics' stock has underperformed the S&P500 Index by -32.31%. Key events include the presentation of interim Phase 1 results for PLN-101095 in December 2025. In March 2026, the company provided a corporate update and reported Fourth Quarter 2025 financial results, with stock changes of +6.02% and -3.76%. In April 2026, updated data from the Phase 1 trial of PLN-101095 were presented, the first patient was dosed in the FORTIFY trial, and the CFO's stock options were repriced. In May 2026, Pliant Therapeutics is expected to participate in the RBC Capital Markets Global Healthcare Conference and announce its Q1 2026 earnings.

As a clinical-stage biopharmaceutical company, Pliant Therapeutics' products are in the development and trial phases, so traditional demand seasonality does not apply. The demand for its products is primarily driven by the progression and success of its clinical trials, regulatory approvals, and the unmet medical needs in the disease areas it targets.

Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing integrin-based therapeutics for fibrotic diseases, solid tumors, and muscular dystrophies. Their key product candidates include Bexotegrast (PLN-74809) for idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC), PLN-101095 for advanced or metastatic solid tumors, and PLN-101325 for muscular dystrophies. The development of bexotegrast in IPF within the BEACON-IPF trial was discontinued following a safety and efficacy review.

Pliant Therapeutics, Inc. is headquartered in South San Francisco, California, United States, with its corporate office located at 260 Littlefield Avenue, San Francisco, CA 94080.

Pliant Therapeutics' reputation is closely tied to its clinical trial outcomes and pipeline progress. The discontinuation of the BEACON-IPF trial and a workforce reduction in 2025 have negatively impacted its reputation. Positive Phase 1 data for PLN-101095 has contributed positively. Wall Street analysts have a "Reduce" consensus rating for the company. Pliant emphasizes its commitment to ESG initiatives.

Pliant Therapeutics, Inc. has significant institutional ownership, ranging from 75.41% to 97.3% of shares. Individual insider ownership stands at 42.31%, with Matthew G. Robinson being the largest individual shareholder. Retail investors hold a smaller portion, around 0.00% to 15.2% of the stock.